Enhance Peptide Innovation With A High-Quality Supply Of Building Blocks

By Brian Graves, Global Business Manager, Grace Fine Chemical Manufacturing Services

The demand for peptide therapeutics continues to grow thanks to their high selectivity and high specificity which can be used to target indications such as metabolic diseases, neurological diseases, and cancers. One major contributor to the growth of peptide therapeutics has been the use of glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide and tirzepatide to treat type 2 diabetes and obesity. Because these drugs are administered via once-a-week injections, they can be costly for patients and challenging for drug sponsors to ensure continuous supply. The overwhelming demand for these therapies has led some sponsors toward developing more accessible and affordable solutions, including peptides designed to require less frequent dosing.

To increase the potency and elongate the half life of peptide compounds, drug manufacturers are leveraging non-canonical amino acids (ncAAs), small peptides, and specialized peptide building blocks to engineer different functionalities. If you are hoping to leverage ncAAs or other unique building blocks to manufacture your drug, establish an early partnership with a knowledgeable chemical material manufacturer to avoid delays en route to commercialization. Download the full article to explore the benefits of unique peptide building blocks and what to look for in a reliable supplier.